Levetiracetam Beta

Levetiracetam, the active ingredient in Levetiracetam Beta, is an anticonvulsant presented as a tablet for oral use. It is employed as adjunctive therapy to control partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy, and may be prescribed by neurologists across various age groups.

GNH USA supplies Levetiracetam Beta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality assurance processes and regulatory compliance, ensuring consistent product integrity and reliable delivery timelines.

Levetiracetam is an antiepileptic drug used as adjunctive therapy for several seizure types. - Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimen. - Generalized tonic‑clonic seizures: helps control convulsive episodes in patients with refractory epilepsy. - Myoclonic seizures: decreases myoclonic jerks as part of combination therapy.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: transient sensation of light‑headedness or unsteadiness, often occurring at treatment initiation. - Fatigue: persistent feeling of tiredness or reduced energy that may affect daily activities. - Headache: mild to moderate cranial pain, sometimes accompanied by photophobia. - Irritability: increased emotional sensitivity, agitation, or short‑tempered behavior. - Nausea: upset stomach that may be accompanied by occasional vomiting. - Somnolence: excessive daytime sleepiness that can impair concentration.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling of face or throat, or difficulty breathing requiring immediate medical attention. - Mood changes: new or worsening depression, anxiety, or suicidal ideation that should be reported promptly. - Hematologic abnormalities: reductions in white blood cells, platelets, or red cells leading to infection risk or bleeding. - Stevens‑Johnson syndrome: rare severe skin reaction with blistering and mucosal involvement. - Hepatic dysfunction: significant elevation of liver enzymes indicating possible liver injury. - Multiorgan failure: extremely rare life‑threatening condition affecting multiple organ systems.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal function: adjust dose in patients with impaired renal clearance. - Psychiatric history: monitor for mood alterations, especially depression or aggression. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy: limited data; evaluate risk‑benefit before use in pregnant women. - Driving and machinery: advise patients about potential dizziness or somnolence affecting performance. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Levetiracetam has a relatively low interaction profile, but certain drug combinations require attention.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma concentrations, decreasing efficacy. - Phenobarbital: can lower levetiracetam levels, potentially compromising seizure control. - Phenytoin: may increase clearance of levetiracetam, requiring close monitoring.

Moderate Interactions (Monitor Closely): - Alcohol: additive central nervous system depression may enhance sedation. - Opioids: combined use can increase risk of respiratory depression and somnolence. - Other antiepileptics (e.g., valproate): may require dose adjustments based on therapeutic response.